Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — Q4 2024 Earnings Presentation
25 slides from Xvivo Perfusion Ab's earnings presentation, Jan 28, 2025
Slide 1: Year-end Report 2024
Year-end Report 2024 Q4 2024 Earnings call, January 28, 2025 Alex Moroianu Heart transplant recipient, AU
Slide 2: Today's presenters
Today’s presenters Christoffer Kristoffer Rosenblad Nordström CEO CFO DOC ID: Year-End Report 2024
Slide 3: Q4 Financials – at a glance
Q4 Financials – at a glance Organic growth Net Sales Thoracic Disposable sales SEK 228 Million Net Sales SEK 152 million +50% Gross margin Disposables 87% Sales growth Organic Abdominal Disposable sales growth 44% Net Sales SEK 50 million Gross margin Disposables 67% +35% - Acquired growth 1% - Curr
Slide 4: YTD Financials – at a glance
YTD Financials – at a glance Organic growth Net Sales Thoracic Disposable sales SEK 822 Million Net Sales SEK 555 million +46% Gross margin Disposables 85% Sales growth Organic Abdominal Disposable sales growth 39% Net Sales SEK 179 million Gross margin Disposables 65% +32% - Acquired growth - % - C
Slide 5: 2024 Highlights
2024 Highlights DOC ID: Year-end report 2024
Slide 6: 2024 Highlights
2024 Highlights 1 Results from XVIVOs European Heart Trial presented in the Lancet 4 Extensive clinical evidence published in prestigious journals and reviews during 2024 on Liver Assist 2 First cross-Atlantic heart transplant facilitated by XVIVO heart technology 5 The use of ex vivo lung perfusion
Slide 7: Significant progress and important publications based on XVIVO technologies in 2024
Significant progress and important publications based on XVIVO technologies in 2024 Thoracic portfolio The use of ex vivo lung perfusion (EVLP) with XVIVOs XPS technology surged in 2024 Publication in The Lancet on the XVIVO European heart trial. A recent study highlighted the clinical value of Resu
Slide 8: Significant progress and important publications based on XVIVO technologies in 2024
Significant progress and important publications based on XVIVO technologies in 2024 Abdominal portfolio Extensive clinical evidence, including randomized trials and a comprehensive Cochrane review, underscores the benefits of XVIVO’s cold A 2024 Cochrane review summarized the perfusion technology (H
Slide 9: Clinical pipeline
Clinical pipeline DOC ID: Year-end report 2024
Slide 10: Clinical Trial Status & Tentative Timeline
Clinical Trial Status & Tentative Timeline REVIEW & PRECLINICAL CLINICAL MARKET APPROVAL FOLLOW-UP • 141 patients included • 1st patient included in October 12 month patient Submission and PMA 13 month patient 2023 follow-up approval process enrollment • Last patient included in HEART November 2024
Slide 11: US PRESERVE Trial recap
US PRESERVE Trial recap • A Prospective, Multi-center, Single-Arm, Open-Label Study of Hearts Transplanted after Non-Ischemic Heart PRESERVation from Extended Donors • High interest in trial resulting in patient enrollment completed ahead of schedule • 141 patients enrolled across 14 trial sites Nex
Slide 12: XVIVO submits IDE application to US FDA to initiate clinical trial with Liver Assist
XVIVO submits IDE application to US FDA to initiate clinical trial with Liver Assist • IDE submitted to FDA in January for review • Purpose of the trial is to generate clinical data to support PMA approval process • Study proposal: DELIVER • Prospective, single-arm, open multicentre clinical trial •
Slide 13: Financial Performance Q4 & YTD
Financial Performance Q4 & YTD DOC ID: Year-End Report 2024
Slide 14: Net sales and results Q4 & YTD
Net sales and results Q4 & YTD Organic sales growth YTD 39% Oct-Dec Oct-Dec Full Year Full Year SEK Million 2024 2023 2024 2023 Net sales 228 156 822 598 Sales growth, % 46 % 18 % 38 % 44 % Whereof organic growth, % 44 % 12 % 39 % 30 % Gross profit 175 117 616 445 Gross margin, % 77 % 75 % 75 % 74 %
Slide 15: Thoracic – Q4 Highlights
Thoracic – Q4 Highlights Net sales by Net sales by Net sales by organ Net Sales region product category SEK 152 million (98) 11% 1% Organic growth disposables 22% 50 % (14) 41% 8% 58% Gross margin disposables 87 % (85) 70% 89% Heart Sales (Q4) Lung Heart Americas Machine perfusion 16million (10) APA
Slide 16: Abdominal – Q4 Highlights
Abdominal – Q4 Highlights Net sales by Net sales by Net Sales Net sales by organ region product category SEK 50 million (38) 2% 20% Organic growth disposables 29% 35 % (22) 0% 2% Gross margin disposables 67 % (69) 71% 78% 98% Liver Kidney Americas Machine perfusion APAC Static preservation EMEA Othe
Slide 17: Services – Q4 Highlights
Services –Q4 Highlights Net Sales Q4 Organ recovery cases YTD Organ recovery highligts Net Sales US Transplant Penetration of all SEK 26 million (19) centers served US Heart/Lung Tx 3 Organic growth 20 5% 16 % (18) 204 470 Acquired growth 266 Flowhawk revenue (SEK) 18 % (-) Q4 - XVIVO LTM 3million 1
Slide 18: EBITDA Q4 & YTD 2024
EBITDA Q4 & YTD 2024 EBITDA (adj), by quarter EBITDA (adj), R12 months Comments SEKm SEKm 250 30% • R12 Trend continues to improve 30% 70 225 • Strong sales growth at solid gross 60 25% 200 25% margin levels as key drivers 183 51 52 50 20% 175 20% • Ambition is to continue improve 151 42 150 137 EBI
Slide 19: Cashflow and financial position (Dec 31, 2024)
Cashflow and financial position (Dec 31, 2024) Cash flow from Cashflow from Q4 Cashflow operating activities (R12) investing activities • Cash flow from operating R12 SEKm Q4 Q4 YTD YTD activities SEK +62 million (18) 150 • Investments SEK -111 million (-53) +111m SEKm 2024 2023 2024 2023 125 Total
Slide 20: Outlook
Outlook Alex Moroianu Heart transplant recipient, AU
Slide 21: Outlook 2025
Outlook 2025 • Continued high interest in EVLP globally • Leverage enthusiasm for hypothermic oxygenated perfusion (HOPE) across organs: Liver, Kidney, Heart • Expected to meet critical milestones related to product commercialization and market expansion: • European approval and launch of XVIVO Hear
Slide 22: XVIVO Strategy 2023-2027
XVIVO Strategy 2023-2027 Purpose Nobody should die waiting for a new organ. Desired Position Preferred partner in the transplant process Financial 30% EBITDA Ambition Accelerate market Strategic Market leader in kidney Change the paradigm Accelerate market leadership in liver objectives perfusion pe
Slide 23: Long term outlook
Long term outlook • The demand for transplants are x 10 of today’s supply • Sales value of machine perfusion vs cold static storage is ~x 10 • Machine perfusion and service models have proven to increase the number of organs used for transplantation • XVIVO has unique, innovative and world leading p
Slide 24: Nobody should die waiting for a new organ
Nobody should die waiting for a new organ DOC ID: Year-End Report 2024
Slide 25: Financial calendar & contacts
Financial calendar & contacts Financial reports 2025 Investor Relations Interim report January - March 2025: April 24, 2025 Christoffer Rosenblad, CEO Telephone: +46 735 19 21 59 Interim report April - June 2025: July 11, 2025 E-mail: christoffer.rosenblad@xvivogroup.com Interim report July – Septem